Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

PHAT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$2.6M, compared with $2.43M a year earlier. Trailing-twelve-month accounts receivables was -$44.36M.

Context

  • Accounts receivables amounted to 22.5% of revenue in FY2025, down 44.8 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$2.6M or moves back toward the trailing-twelve-month quarterly average of -$11.09M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.6M-88.4% QoQ
Last fiscal yearDec 2025
-$39.33M+5.8% YoY
LTMMar 2026
-$44.36M+36.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-206.7%——
1 year+5.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(39.33M) USD
Year-over-year change
-5.8%

Accounts Receivables vs competitors

How PHAT compares with its peers on the latest reported figures

  • PHAT's LTM Mar 2026 accounts receivables of $44.36M is the largest of the 2 companies compared; the peer median is $36.37M.
  • Its year-over-year change of +36.6% is the lowest of 2, against a peer median of +98.7%.
  • Accounts receivables amounts to 21.7% of revenue for PHAT, versus a peer median of 8.5%.
PHAT Competitors Peer median
Accounts Receivables for PHAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$44.36M +36.6%—21.7%
ARDXArdelyx, Inc.LTM Mar 2026$36.37M +98.7%+25.1%8.5%
Peer median (excluding PHAT) $36.37M+98.7%+25.1%8.5%

Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Depreciation & Amortization521K620K575K795K633K
Deferred Income Tax00000
Stock-Based Compensation16.81M24.13M45.03M24.05M28.72M
Change in Working Capital(27.32M)5.44M(13.64M)(15.3M)(12.38M)
Accounts Receivables00(1.64M)(37.16M)(39.33M)
Inventory00(9.44M)(6.14M)(11.78M)
Accounts Payables(9.79M)8.68M6.41M34.94M34.1M
Other Working Capital(17.52M)(3.24M)(8.98M)(6.93M)4.63M
Other Non-Cash Items5.41M21M32.06M58.01M37.5M
Operating Cash Flow(148.46M)(146.53M)(137.58M)(266.77M)(166.78M)
Capital Expenditures(328K)(1.04M)(1.63M)(135K)(229K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(328K)(1.04M)(1.63M)(135K)(229K)
Debt Repayment42.76M95.45M39.32M59.4M0
Common Stock Issued024.6M155.46M121.78M1.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.94M0172.8M1.6M(1.93M)
Financing Cash Flow44.71M120.04M367.58M182.77M(288K)
Effect of Forex Changes0(345K)000
Net Change in Cash(104.08M)(27.87M)228.37M(84.13M)(167.29M)
Free Cash Flow(148.79M)(147.57M)(139.21M)(266.91M)(166.78M)

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Intrinsic Alpha fair value

Locked

Current Price

$5.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.